AIP insider Paul Alpern executed 5,000-share exercise and sale on 10/01/2025

Rhea-AI Filing Summary

Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), reported transactions dated 10/01/2025 executed under a 10b5-1 trading plan adopted on June 5, 2025. The reporting person acquired 5,000 shares (transaction code M) at an effective price of $0.56 and sold 5,000 shares (transaction code S) at a weighted average price of $10.3089, with sale prices ranging from $10.16 to $10.51. After the transactions, the report shows 73,587 shares beneficially owned as to the non-derivative holdings and 85,000 shares when including derivative securities. The derivative shown is an option with a $0.56 exercise price exercisable beginning 10/01/2025 and expiring 10/23/2029. The filing is signed and dated 10/03/2025.

Positive

• Transaction executed under a 10b5-1 plan adopted on June 5, 2025, indicating pre-established trading instructions
• Sale price disclosed as a weighted average of $10.3089 with a reported per-trade range of $10.16–$10.51, providing transparency on execution
• Derivative option remains outstanding with exercisable date 10/01/2025 and expiration 10/23/2029, and 85,000 shares total beneficially owned including derivatives

Negative

• Non-derivative holdings decreased by 5,000 shares to 73,587 following the sale
• Multiple sales occurred (prices ranged across $10.16–$10.51), which may complicate simple interpretation of proceeds without per-trade breakdown

Insights

Securities Trading Expert

TL;DR: Insider exercised and immediately sold 5,000 shares under a pre-established 10b5-1 plan.

The report shows a concurrent exercise (or deemed acquisition) of 5,000 shares at $0.56 and a sale of 5,000 shares at a weighted average of $10.3089. The seller discloses the sale price range ($10.16–$10.51), which indicates the sale occurred in multiple transactions.

This was executed under a disclosed 10b5-1 trading plan adopted on June 5, 2025, which documents pre-clearance and timing rules reducing the likelihood of impermissible insider trading claims.

Corporate Governance Analyst

TL;DR: Insider holdings remain material but were modestly reduced after the trade.

Non-derivative beneficial ownership following the reported transactions is 73,587 shares; including derivative securities the filing lists 85,000 shares beneficially owned. The filing also discloses a vesting schedule for the derivative shares that began vesting on August 26, 2020 with monthly vesting thereafter.

Filing is signed and dated 10/03/2025, providing an auditable record of the insider's activity as required under Section 16.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Alpern Paul L

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CA 95008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP and General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M(1)		5,000	A	$0.56	78,587	D
Common Stock	10/01/2025		S(1)		5,000	D	$10.3089(2)	73,587	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock	$0.56	10/01/2025		M			5,000	(3)	10/23/2029	Common Stock	5,000	$0.00	85,000	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on June 5, 2025.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.51 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. 25% of the total shares vested on August 26, 2020; thereafter, 1/48th of the total shares vested monthly for 3 years, beginning on September 26,2020.

Remarks:

	/s/ Paul Alpern	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Arteris insider Paul L. Alpern report on Form 4 (AIP)?

The filing reports that Paul L. Alpern acquired 5,000 shares at $0.56 and sold 5,000 shares at a weighted average price of $10.3089 on 10/01/2025 under a 10b5-1 plan.

When was the 10b5-1 trading plan adopted for the transactions?

The Form 4 states the 10b5-1 plan was adopted on June 5, 2025.

How many shares does Paul L. Alpern beneficially own after these transactions?

The filing shows 73,587 shares beneficially owned for non-derivative securities and 85,000 shares when including derivative securities.

What price range were the sold shares executed at?

The shares sold were executed at prices ranging from $10.16 to $10.51, with a reported weighted average of $10.3089.

Are there any outstanding options or derivatives disclosed?

Yes. The filing discloses a derivative with an exercise price of $0.56, exercisable 10/01/2025 and expiring 10/23/2029, underlying 5,000 shares.